FFAR4 and colitis: In murine colitis models, Salaga et al. showed that the intraperitoneal administration of the selective FFAR4 agonist GSK137647 (1 mg kg−1, twice daily) ameliorated DSS- and TNBS-induced disease, as evidenced by reduced body-weight loss, improved macroscopic and histological scores, and a significant reduction in colonic myeloperoxidase activity, indicating dampened neutrophil-driven inflammation [69].